Nisa Investment Advisors LLC Sells 21,945 Shares of Neurocrine Biosciences, Inc. $NBIX

Nisa Investment Advisors LLC trimmed its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 80.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,201 shares of the company’s stock after selling 21,945 shares during the period. Nisa Investment Advisors LLC’s holdings in Neurocrine Biosciences were worth $738,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. USA Financial Formulas acquired a new stake in shares of Neurocrine Biosciences in the fourth quarter valued at approximately $25,000. Golden State Wealth Management LLC lifted its holdings in Neurocrine Biosciences by 120.5% during the 3rd quarter. Golden State Wealth Management LLC now owns 183 shares of the company’s stock worth $26,000 after buying an additional 100 shares in the last quarter. Eastern Bank bought a new position in Neurocrine Biosciences in the 3rd quarter valued at $27,000. Geneos Wealth Management Inc. boosted its position in Neurocrine Biosciences by 143.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after buying an additional 135 shares during the last quarter. Finally, Quent Capital LLC acquired a new stake in shares of Neurocrine Biosciences in the 3rd quarter valued at $32,000. 92.59% of the stock is owned by institutional investors.

Insider Activity

In other news, CEO Kyle Gano sold 36,400 shares of the business’s stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $132.70, for a total transaction of $4,830,280.00. Following the completion of the transaction, the chief executive officer directly owned 140,407 shares in the company, valued at approximately $18,632,008.90. The trade was a 20.59% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 4.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. JPMorgan Chase & Co. upped their price target on Neurocrine Biosciences from $176.00 to $177.00 and gave the company an “overweight” rating in a research note on Thursday, March 12th. Royal Bank Of Canada lowered their price objective on Neurocrine Biosciences from $180.00 to $177.00 and set an “outperform” rating for the company in a research report on Thursday, February 12th. Wells Fargo & Company dropped their price objective on Neurocrine Biosciences from $180.00 to $175.00 and set an “overweight” rating for the company in a report on Friday, February 13th. Wall Street Zen downgraded shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Monday, February 16th. Finally, Wedbush raised their target price on shares of Neurocrine Biosciences from $149.00 to $151.00 and gave the company an “outperform” rating in a research note on Thursday, February 12th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Neurocrine Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $175.10.

Neurocrine Biosciences Price Performance

NASDAQ:NBIX opened at $131.60 on Friday. Neurocrine Biosciences, Inc. has a 12-month low of $84.23 and a 12-month high of $160.18. The firm has a market capitalization of $13.21 billion, a P/E ratio of 28.24, a P/E/G ratio of 0.69 and a beta of 0.35. The stock’s fifty day simple moving average is $131.56 and its 200-day simple moving average is $139.12.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Wednesday, February 11th. The company reported $1.88 EPS for the quarter, missing analysts’ consensus estimates of $2.36 by ($0.48). Neurocrine Biosciences had a net margin of 16.73% and a return on equity of 16.48%. The company had revenue of $805.50 million during the quarter, compared to the consensus estimate of $804.21 million. During the same quarter in the prior year, the company posted $1.69 EPS. The company’s revenue for the quarter was up 28.3% compared to the same quarter last year. As a group, equities research analysts expect that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current year.

Neurocrine Biosciences Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.